RevBio key facts
- Developer of regenerative adhesive biomaterial, designed to facilitate bone repair and regeneration in medical procedures.
- It has raised $45.8M across 2 recorded rounds; the latest was Early Stage VC ($10.0M) in Apr 2023.
- Notable investors include MassChallenge, MedTech Innovator, The JHA Capital, Beacon Angels, Greyhill Ventures — 18 tracked in total.
- RevBio has filed 5 Form Ds with the SEC since 2021, most recently Jul 2025 ($10.0M sold to 54 investors).
- Status: Privately Held (backing).
Who backs RevBio
18+Membership and data by Private Market View
- ·The complete investor list: 18 names
- ·Watch RevBio: the Monday email on marks, rounds and moves
RevBio funding rounds
2 roundsHow much has RevBio raised?
RevBio has raised $45.8 million in total; 2 of its rounds are on record. The largest on record was a $9 million early-stage round in Jun 2021; the most recent was a $10 million early-stage round in Apr 2023.
RevBio has filed 5 Form Ds with the SEC since 2021, most recently in Jul 2025 ($10 million sold to 54 investors).
RevBio investors
18 investors are on record for RevBio, including MassChallenge, MedTech Innovator, The JHA Capital and Beacon Angels. The early-stage round in Apr 2023 drew 54 investors.
About RevBio
Developer of regenerative adhesive biomaterial, designed to facilitate bone repair and regeneration in medical procedures. The company offers an injectable, biocompatible material that adheres to wet bone, promotes new bone growth, and resorbs over time, enabling dental and orthopedic specialists with stable fixation and support for natural healing.
- Sector
- Healthcare
- HQ
- Lowell, MA, United States
- Founded
- 2014
- Employees
- 33
- Website
- revbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
RevBio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.